Ulcerative Colitis Clinical Trial
Official title:
Positron Emission Tomography With 18F-fluorodeoxyglucose Combined With MRI for Monitoring Inflammatory Activity in Patients With Ulcerative Colitis
NCT number | NCT03781284 |
Other study ID # | 360668 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 1, 2016 |
Est. completion date | October 31, 2018 |
Verified date | December 2018 |
Source | Universität Duisburg-Essen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Colonoscopy is considered crucial for the diagnosis and quantification of ulcerative colitis
(UC). However, there are several drawbacks related to the invasiveness, procedure-related
discomfort, risk of bowel perforation (especially in the period of acute inflammation), and
relatively poor patient acceptance. Most patients regard the necessary bowel cleansing as
burdensome. Feasible, accurate and well accepted non-invasive diagnostic techniques are
needed for the determination of inflammatory activity and optimal tailoring of therapy.
Hybrid PET/MRI represents an innovative combination of two established, non-invasive
diagnostic tools: Magnetic resonance imaging (MRI), allowing for anatomic-functional imaging
of the abdomen at high soft tissue contrast and positron emission tomography (PET) utilizing
18F-fluorodeoxyglucose (FDG) a non-invasive tool to monitor glucose metabolism and allowing a
detection and quantification of inflammatory processes. Since MRI has limited sensitivity in
UC and may be hampered by retained stool, a combination with another imaging modality is very
appealing. PET, on the other side provides functional information, yet with limited
anatomical landmarks and is relatively unsusceptible to artifacts associated to retained
stool. In combination, these modalities might provide a valid alternative for the
non-invasive assessment of the inflammatory activity in UC patients without the need for
bowel purgation. It will therefore have to be investigated whether fecal material does impede
the diagnostic quality of the combination of FDG-PET and MRI. For this purpose, the
investigators will include 50 patients with confirmed ulcerative colitis. Dependent on
clinical activity of the inflammation, patients will be randomized to undergo PET/MRI
enterography either with or without prior bowel purgation followed by a colonoscopy.
Inflammatory activity in 7 bowel segments will be analyzed based on PET/MRI with and without
bowel purgation with the results of colonoscopy as standard of reference.
Patient acceptance of PET/MRI with and without bowel purgation as well as colonoscopy will be
compared. PET/MRI with and without bowel cleansing will be compared with regard to diagnostic
accuracy as well as for its patients' acceptance in comparison to colonoscopy.
The investigators hypothesize that PET/MRI will eventually be highly accurate to detect and
monitor inflammatory activity in patients with ulcerative colitis. Additional information
about extra-intestinal findings might also change the therapeutic concept. PET/MRI might
serve as a non-invasive diagnostic option in patients with UC to quantify inflammatory
activity especially when bowel cleansing or colonoscopy is not applicable.
Status | Completed |
Enrollment | 53 |
Est. completion date | October 31, 2018 |
Est. primary completion date | October 31, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - patients with confirmed ulcerative colitis verified by the defining symptoms (rectal bleeding, diarrhea), endoscopy and histopathology - clinically indicated colonoscopy and 18F-FDG PET as either initial assessment or follow- up examination - patient age = 18 years Exclusion Criteria: - Patients aged < 18years - Patients with MRI contraindications, e.g. presence of cardiac pacemaker, implanted cardioverter-defibrillator, neurostimulation systems or with claustrophobia. - acute renal failure, severe chronic renal failure (calculated glomerular filtration rate [GFR] < 30 ml/min) - allergy to i.v. gadolinium based contrast agents |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Universität Duisburg-Essen | Crohn's & Colitis Foundation |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic accuracy of PET/MRI with and without bowel purgation | Overall segment-based diagnostic accuracy using ileocolonoscopy as reference standard will be calculated for PET/MRI with and without bowel purgation | 24 hours | |
Secondary | Sensitivity of PET/MRI with and without bowel purgation in percent | Overall segment-based sensitivity using ileocolonoscopy as reference standard will be calculated for PET/MRI with and without bowel purgation | 24 hours | |
Secondary | Specificity of PET/MRI with and without bowel purgation in percent | Overall segment-based specificity using ileocolonoscopy as reference standard will be calculated for PET/MRI with and without bowel purgation | 24 hours | |
Secondary | Negative predictive value of PET/MRI with and without bowel purgation in percent | Overall segment-based negative predictive value using ileocolonoscopy as reference standard will be calculated for PET/MRI with and without bowel purgation | 24 hours | |
Secondary | Positive predictive value of PET/MRI with and without bowel purgation in percent | Overall segment-based positive predictive value using ileocolonoscopy as reference standard will be calculated for PET/MRI with and without bowel purgation | 24 hours | |
Secondary | Optimized cut-offs | Optimized cut-offs for PET for each bowel segment using ileocolonoscopy as reference standard for each colon segment will be calculated | 24 hours | |
Secondary | Patient acceptance | 18F-FDG PET/MRI without bowel cleansing shows higher patient acceptance than conventional colonoscopy | 24 hours | |
Secondary | Description of extraintestinal findings | Extraintestinal findings will be assessed by evaluating PET/MRI images | 24 hours | |
Secondary | The Boston Bowel Preparation Scale | Bowel Preparation Quality will be assessed for both patient groups | 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |